Cantor Fitzgerald Cuts Earnings Estimates for Disc Medicine

Disc Medicine, Inc. (NASDAQ:IRON - Free Report) - Stock analysts at Cantor Fitzgerald lowered their FY2025 earnings estimates for Disc Medicine in a research report issued on Thursday, May 8th. Cantor Fitzgerald analyst K. Kluska now forecasts that the company will post earnings per share of ($4.69) for the year, down from their previous forecast of ($4.59). Cantor Fitzgerald has a "Overweight" rating and a $132.00 price objective on the stock. The consensus estimate for Disc Medicine's current full-year earnings is ($4.07) per share.

Disc Medicine (NASDAQ:IRON - Get Free Report) last issued its earnings results on Wednesday, May 7th. The company reported ($1.02) earnings per share for the quarter, missing the consensus estimate of ($0.99) by ($0.03).

A number of other equities analysts have also weighed in on the stock. HC Wainwright reiterated a "buy" rating and issued a $118.00 price objective on shares of Disc Medicine in a research report on Tuesday, January 21st. Stifel Nicolaus lifted their price target on Disc Medicine from $90.00 to $94.00 and gave the stock a "buy" rating in a research note on Friday, January 24th. Morgan Stanley reaffirmed an "overweight" rating and set a $85.00 price target on shares of Disc Medicine in a research note on Friday, March 7th. TD Cowen started coverage on Disc Medicine in a research note on Thursday, February 27th. They set a "buy" rating for the company. Finally, BMO Capital Markets lifted their price target on Disc Medicine from $112.00 to $120.00 and gave the stock an "outperform" rating in a research note on Monday. Ten investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of "Buy" and an average target price of $98.80.

Disc Medicine Trading Up 1.2%

NASDAQ:IRON traded up $0.58 during mid-day trading on Monday, hitting $47.67. The stock had a trading volume of 145,875 shares, compared to its average volume of 348,459. The stock has a 50-day simple moving average of $46.21 and a two-hundred day simple moving average of $54.87. Disc Medicine has a twelve month low of $30.65 and a twelve month high of $68.73. The company has a market capitalization of $1.65 billion, a PE ratio of -11.99 and a beta of 0.77.

Insider Buying and Selling

In related news, CFO Jean M. Franchi sold 3,136 shares of the firm's stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $54.58, for a total value of $171,162.88. Following the transaction, the chief financial officer now directly owns 69,530 shares of the company's stock, valued at approximately $3,794,947.40. This trade represents a 4.32% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, COO Jonathan Yen-Wen Yu sold 1,610 shares of Disc Medicine stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $54.58, for a total value of $87,873.80. Following the completion of the transaction, the chief operating officer now directly owns 40,555 shares in the company, valued at approximately $2,213,491.90. This represents a 3.82% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 356,290 shares of company stock valued at $19,336,901. Corporate insiders own 4.24% of the company's stock.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in IRON. Barclays PLC increased its position in shares of Disc Medicine by 123.7% during the third quarter. Barclays PLC now owns 40,145 shares of the company's stock valued at $1,972,000 after purchasing an additional 22,202 shares during the period. JPMorgan Chase & Co. boosted its stake in Disc Medicine by 16.1% in the third quarter. JPMorgan Chase & Co. now owns 16,255 shares of the company's stock worth $799,000 after purchasing an additional 2,257 shares in the last quarter. SG Americas Securities LLC boosted its stake in Disc Medicine by 66.0% in the fourth quarter. SG Americas Securities LLC now owns 8,076 shares of the company's stock worth $512,000 after purchasing an additional 3,212 shares in the last quarter. China Universal Asset Management Co. Ltd. lifted its stake in shares of Disc Medicine by 10.4% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 6,310 shares of the company's stock valued at $400,000 after acquiring an additional 593 shares during the period. Finally, Bleakley Financial Group LLC acquired a new position in shares of Disc Medicine during the fourth quarter valued at $486,000. 83.70% of the stock is owned by institutional investors.

About Disc Medicine

Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.